Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PYRZ, also known as 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one, is a novel cytotoxic heterocycle structurally related to temozolomide. Despite its structural similarities to temozolomide, PYRZ exhibits a distinct mechanism of action. It inhibits the synthesis of DNA, RNA, and protein, and induces dose-dependent DNA fragmentation. This leads to an accumulation of cells in the late S and G2+M phases of the cell cycle. PYRZ has demonstrated significant cell-killing kinetics in human epithelial ovarian cancer cell lines, with 50-90% cell killing observed within 24 hours at micromolar concentrations. Its mechanism of action is considered atypical for 1,2,3-triazene-containing alkylating agents, as it shows only background levels of DNA alkylation compared to temozolomide.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one.